Project Grant K01AI190051
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $189K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This $195,101 Project Grant, awarded by the National Science Foundation's (NSF) Biological Sciences program (CFDA 47.074), will use mathematical modeling to project the healthcare burden associated with COVID-19, influenza, and respiratory syncytial virus (RSV) in the United States during the 2023-2024 respiratory virus season. The research will integrate estimates of population immunity from prior infections, vaccinations, and monoclonal antibody therapy to produce four rounds of projections...
- This $3,304,164 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to determine the real-world comparative effectiveness, cost-effectiveness, safety, and impact of the recently approved maternal respiratory syncytial virus (RSV) vaccine and extended-half-life monoclonal antibody products in reducing RSV-associated respiratory morbidities in infants and...
- This $160,546 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research towards developing a novel spatiotemporal machine learning framework for epidemic models of respiratory infections. The award to Emory University in Atlanta, Georgia, with a period of performance from September 3, 2025 through August 31, 2029, aims to advance foundational epidemiological...
- This $457,778 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a human microphysiological system (MPS) to investigate the peripheral nervous system (PNS) neurotropism of respiratory syncytial virus (RSV) and SARS-CoV-2. The research aims to elucidate the underlying mechanisms contributing to chronic neurological impairments associated with RSV and...
- The Project Grant award of $378,893 from the National Institute of Nursing Research (NINR), under the CFDA 93.361 Nursing Research program, will fund the integration of AI nowcasting models with digital communications to reduce respiratory syncytial virus (RSV) infections in rural areas. The project aims to build and operationalize a tailored spatio-temporal AI model to accurately predict RSV infection rates and deliver timely, targeted health messaging through trusted community channels like...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $429,000 from August 1, 2025 to July 31, 2027 to researchers at the University of Texas at Dallas (UTD). The project aims to develop innovative methods for measuring the distribution and viability of viruses in bioaerosols, focusing on sub-5mm and submicron particles that can transmit long distances....
- This $175,000 Project Grant awarded by the National Science Foundation (NSF) Biological Sciences program (CFDA 47.074) will develop new computational models and forecasting approaches to predict the incidence and severity of respiratory illnesses like COVID-19, influenza, and RSV for the 2024-2025 season. The project aims to combine computational modeling with human judgment to improve the accuracy and responsiveness of public health forecasting on a national scale. It will deliver weekly...
- This Project Grant award of $364,484, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop novel bronchodilators to alleviate respiratory distress in young children infected with Respiratory Syncytial Virus (RSV). The awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will screen 8 clinically relevant soluble guanylate cyclase (SGC)...
- This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), is supporting a $182,726 research initiative led by Dr. Sara Kim at Seattle Children's Hospital and the University of Washington. The project aims to understand the immune parameters associated with preventing Respiratory Syncytial Virus (RSV) lower respiratory tract infections in hematopoietic cell transplant recipients, a population at high...
- This $779,170 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to determine the burden of rhinoviruses (RVs) as a cause of severe respiratory illnesses leading to hospitalization in children. The 5-year study, starting on August 15, 2025, will create a longitudinal cohort of children in Madison, Wisconsin to identify circulating RVs and establish a nasal transcriptome to differentiate clinical RV...